Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis
A. Achiron, E. Pras, R. Gilad, I. Ziv, M. Mandel, C. R. Gordon, S. Noy, I. Sarova-Pinhas and E. Melamed
Department of Neurology, Beilinson Medical Center, Petah-Tiqva, Israel.
Ten patients with relapsing-remitting multiple sclerosis were treated with
intravenous immune globulin, 0.4 g/kg per day for 5 consecutive days, and
then with additional booster doses of immune globulin of 0.4 g/kg, once
every 2 months, for the next 12 months. Ten untreated patients with
relapsing-remitting multiple sclerosis who were matched with the study
patients for age, disease duration, and number of attacks per year served
as controls. Immune globulin treatment was well tolerated, with no side
effects. The exacerbation rate decreased from 3.7 +/- 1.2 exacerbations per
year before treatment to 1.0 +/- 0.7 exacerbations per year during the
treatment in the immune globulin-treated patients, while it remained
unaltered in the controls. The posttreatment Kurtzke Expanded Disability
Status Scale score decreased from a mean of 4.45 to 4.15, whereas in
controls it increased from 3.55 to 3.75. The results suggest that immune
globulin suppresses the ongoing pathologic process in multiple sclerosis
and may be a promising treatment to prevent disease exacerbations.
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
Kremenchutzky et al.
Brain 2006;129:584-594.
ABSTRACT
| FULL TEXT
No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis
Petereit et al.
Mult Scler 2006;12:66-71.
ABSTRACT
Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis
Warrington et al.
Proc. Natl. Acad. Sci. USA 2000;97:6820-6825.
ABSTRACT
| FULL TEXT
Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes
Sorensen
Arch Neurol 1999;56:1025-1027.
FULL TEXT
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?: No
Karussis and Abramsky
Arch Neurol 1999;56:1028-1032.
FULL TEXT
Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis?
Mcgavern et al.
Neuroscientist 1999;5:19-28.
ABSTRACT
A unique population of circulating autoantibodies promotes central nervous system remyelination
Asakura and Rodriguez
Mult Scler 1998;4:217-221.
ABSTRACT
Intravenous Immunoglobulin Treatment of Children With Autism
Plioplys
J Child Neurol 1998;13:79-82.
ABSTRACT
